Supernus Pharmaceuticals Stock Probability of Future Stock Price Finishing Under 31.29
| SUPN Stock | USD 37.18 0.90 2.48% |
Supernus |
Supernus Pharmaceuticals Target Price Odds to finish below 31.29
The tendency of Supernus Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 31.29 or more in 90 days |
| 37.18 | 90 days | 31.29 | under 4 |
Based on a normal probability distribution, the odds of Supernus Pharmaceuticals to drop to $ 31.29 or more in 90 days from now is under 4 (This Supernus Pharmaceuticals probability density function shows the probability of Supernus Stock to fall within a particular range of prices over 90 days) . Probability of Supernus Pharmaceuticals price to stay between $ 31.29 and its current price of $37.18 at the end of the 90-day period is about 83.91 .
Given the investment horizon of 90 days Supernus Pharmaceuticals has a beta of 0.18. This usually implies as returns on the market go up, Supernus Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Supernus Pharmaceuticals will be expected to be much smaller as well. Additionally Supernus Pharmaceuticals has an alpha of 0.3308, implying that it can generate a 0.33 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Supernus Pharmaceuticals Price Density |
| Price |
Predictive Modules for Supernus Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Supernus Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Supernus Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Supernus Pharmaceuticals is not an exception. The market had few large corrections towards the Supernus Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Supernus Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Supernus Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.33 | |
β | Beta against Dow Jones | 0.18 | |
σ | Overall volatility | 1.99 | |
Ir | Information ratio | 0.17 |
Supernus Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Supernus Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Supernus Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Supernus Pharmaceuticals currently holds 41.53 M in liabilities with Debt to Equity (D/E) ratio of 0.53, which is about average as compared to similar companies. Supernus Pharmaceuticals has a current ratio of 0.83, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Supernus Pharmaceuticals' use of debt, we should always consider it together with its cash and equity. | |
| Over 95.0% of Supernus Pharmaceuticals shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Jonathan Rubin of 750 shares of Supernus Pharmaceuticals subject to Rule 16b-3 |
Supernus Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Supernus Stock often depends not only on the future outlook of the current and potential Supernus Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Supernus Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 55.5 M | |
| Cash And Short Term Investments | 254.9 M |
Supernus Pharmaceuticals Technical Analysis
Supernus Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Supernus Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Supernus Pharmaceuticals. In general, you should focus on analyzing Supernus Stock price patterns and their correlations with different microeconomic environments and drivers.
Supernus Pharmaceuticals Predictive Forecast Models
Supernus Pharmaceuticals' time-series forecasting models is one of many Supernus Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Supernus Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Supernus Pharmaceuticals
Checking the ongoing alerts about Supernus Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Supernus Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Supernus Pharmaceuticals currently holds 41.53 M in liabilities with Debt to Equity (D/E) ratio of 0.53, which is about average as compared to similar companies. Supernus Pharmaceuticals has a current ratio of 0.83, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Supernus Pharmaceuticals' use of debt, we should always consider it together with its cash and equity. | |
| Over 95.0% of Supernus Pharmaceuticals shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Jonathan Rubin of 750 shares of Supernus Pharmaceuticals subject to Rule 16b-3 |
Check out Supernus Pharmaceuticals Backtesting, Supernus Pharmaceuticals Valuation, Supernus Pharmaceuticals Correlation, Supernus Pharmaceuticals Hype Analysis, Supernus Pharmaceuticals Volatility, Supernus Pharmaceuticals History as well as Supernus Pharmaceuticals Performance. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share 1.07 | Revenue Per Share 11.877 | Quarterly Revenue Growth 0.142 | Return On Assets 0.0289 |
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.